Miura Partners Acquires HTBA (HealthTech BioActives)
November 5, 2024
Miura Partners has signed an agreement to acquire HTBA (HealthTech BioActives), a Barcelona-headquartered producer of flavonoids and active vitamin B12 used across pharmaceutical, nutraceutical, food & beverage and animal nutrition markets. Miura will pursue organic and inorganic initiatives to consolidate HTBA as a leading platform for natural ingredients; the deal is the third investment from Miura Fund IV and is pending approval from the Spanish regulator.
- Buyers
- Miura Partners
- Targets
- HTBA (HealthTech BioActives)
- Industry
- Biotechnology
- Location
- Catalonia, Spain
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
USANA Health Sciences Acquires 78.8% Stake in Hiya Health
December 23, 2024
Consumer Products
USANA Health Sciences acquired a 78.8% controlling stake in Hiya Health Products, LLC for approximately $205 million in cash, closing December 23, 2024. The acquisition expands USANA's direct-to-consumer presence in the children's health and wellness market and is expected to be accretive to USANA's 2025 adjusted EBITDA.
-
Miura Partners Acquires 20% Stake in Bianna to Launch Bianna Renting Services
May 23, 2024
Environmental Services
Miura Partners' Impact Fund acquired a 20% stake in Bianna through a capital increase to fund the company's expansion and to create Bianna Renting Services, a rental business for waste treatment equipment and turnkey solutions. Bianna, founded in 1990 and based in Girona, Spain, operates globally with four production centers and six commercial branches, employs over 200 people and reported revenues above €50 million in 2023.
-
biote Corp Acquires Asteria Health
January 17, 2024
Healthcare Services
biote Corp. (NASDAQ: BTMD) announced a definitive agreement to acquire F.H. Investments, Inc., doing business as Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The deal is intended to strengthen biote’s control over its supply chain through vertical integration of hormone product manufacturing and expand biote’s capabilities in 503B manufacturing and product development.
-
Charme Capital Partners and Miura Capital Acquire INDIBA from Magnum
February 28, 2022
Medical Devices
Private equity firms Charme Capital Partners and Miura Capital have completed the acquisition of INDIBA, a Barcelona-based developer of 448 kHz radio-frequency medical devices for physiotherapy, aesthetics and veterinary markets, from Magnum. The deal positions INDIBA for a next phase of growth, with plans to expand market reach, product portfolio and operations under the new ownership.
-
Montagu Acquires Majority Stake in HTL Biotechnology
February 28, 2022
Pharmaceuticals
Montagu, a leading private equity firm, has acquired a majority stake in HTL (HTL Biotechnology) from Bridgepoint, with minority shareholders Naxicap and Téthys Invest retaining their holdings. Montagu will support HTL's international expansion, R&D and premium product positioning and has appointed Paul Navarre as Chairman to help drive the company's next growth phase.
-
The Riverside Company Acquires HealthTech BioActives (HTBA) from Ferrer
December 13, 2019
Pharmaceuticals
The Riverside Company has acquired HealthTech BioActives S.L. (HTBA), a Spanish manufacturer of APIs, excipients, natural flavors and vitamin B12 derivatives, in a carve-out from Ferrer. Riverside will work with HTBA’s ~140 employees and its manufacturing sites in Beniel (Murcia) and Barcelona to strengthen commercial capabilities, accelerate new product development and expand global sales.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.